1. Sampson, UK, Fowkes, FG, McDermott, MM, et al. Global and regional burden of death and disability from peripheral artery disease: 21 world regions, 1990 to 2010. Glob Heart 2014; 9: 145–158.e21.
Google Scholar2. Norgren, L, North, R, Baumgartner, I, et al. World regional differences in outcomes for patients with peripheral artery disease: EUCLID trial. Vasc Med. Published online Sept 13, 2021. DOI: 10.1177/1358863X211038620.
Google Scholar | Crossref3. Woo, KS, Nicholls, MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 1995; 40: 141–144.
Google Scholar | Medline | ISI4. Brown, T, Forster, RB, Cleanthis, M, et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev 2021; 6: CD003748.
Google Scholar | Medline5. de Donato, G, Setacci, F, Mele, M, et al. Restenosis after coronary and peripheral intervention: Efficacy and clinical impact of cilostazol. Ann Vasc Surg 2017; 41: 300–307.
Google Scholar | Crossref | Medline6. Abtan, J, Bhatt, DL, Elbez, Y, et al.; REACH Registry Investigators . Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry. Clin Cardiol 2017; 40: 710–718.
Google Scholar | Crossref | Medline7. Bauersachs, R, Brodmann, M, Clark, C, et al.; EUROPAD Writing Group . International public awareness of peripheral artery disease. Vasa 2021; 50: 294–300.
Google Scholar | Crossref | Medline8. McDowell, S, Coleman, J, Ferner, R. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006; 332: 1177–1181.
Google Scholar | Crossref | Medline9. Ferrari, R, Ford, I, Greenlaw, N, et al.; CLARIFY Registry Investigators . Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: Data from the contemporary CLARIFY registry. Eur J Prev Cardiol 2015; 22: 1056–1065.
Google Scholar | SAGE Journals | ISI10. Ducrocq, G, Bhatt, DL, Labreuche, J, et al. Geographic differences in outcomes in outpatients with established atherothrombotic disease: Results from the REACH Registry. Eur J Prev Cardiol 2014; 21: 1509–1516.
Google Scholar | SAGE Journals | ISI11. Cho, HL, Danis, M, Grady, C. The ethics of uninsured participants accessing healthcare in biomedical research: A literature review. Clin Trials 2018; 15: 509–521.
Google Scholar | SAGE Journals | ISI12. Svensson, K, Ramírez, OF, Peres, F, et al. Socioeconomic determinants associated with willingness to participate in medical research among a diverse population. Contemp Clin Trials 2012; 33: 1197–1205.
Google Scholar | Crossref | Medline | ISI13. Kim, LK, Swaminathan, RV, Minutello, RM, et al. Trends in hospital treatments for peripheral arterial disease in the United States and association between payer status and quality of care/outcomes, 2007–2011. Catheter Cardiovasc Interv 2015; 86: 864–872.
Google Scholar | Crossref | Medline14. Vart, P, Coresh, J, Kwak, L, et al. Socioeconomic status and incidence of hospitalization with lower-extremity peripheral artery disease: Atherosclerosis Risk in Communities Study. J Am Heart Assoc 2017; 6: e004995.
Google Scholar | Crossref | Medline15. Pfeffer, MA, Claggett, B, Assmann, SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015; 131: 34–42.
Google Scholar | Crossref | Medline | ISI16. Dos Santos, M, Sharma, A, Sun, J-L, et al. International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the NAVIGATOR Trial. J Am Heart Assoc 2017; 6: e0038912.
Google Scholar